Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Neighborhood Access to Healthy Food Affects Residents’ Risk of Atherosclerosis

Leah Lawrence

August 22, 2016

News Industry News

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

July 11, 2016

News Daily News

Amount of Calcium, Not Calcium Progression, May Be Best for Gauging CV Risk

Michael H. Wilson

July 07, 2016

News Daily News

新分析质疑低密度脂蛋白胆固醇“越低越好”的说法，但专家仍呼吁应注意

Todd Neale

June 22, 2016

News Daily News

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Todd Neale

June 22, 2016

News Daily News

Mammogram-Derived Clues to Cardiovascular Disease Often Unreported and Ignored

L.A. McKeown

March 25, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Industry News

Lilly Provides Update on Evacetrapib Phase 3 Trial

July 27, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

August 28, 2014

News Daily News

Post Angiography Testosterone Therapy Increases Cardiovascular Events in High-Risk Men

December 05, 2013

News Industry News

Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN

September 27, 2011

News Conference News

Endothelial Shear Stress Works as a PREDICTION Tool

April 05, 2011

News Daily News

Calcium Scanning May Lower CAD Risk at No Extra Cost

March 23, 2011

Advertisement

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Neighborhood Access to Healthy Food Affects Residents’ Risk of Atherosclerosis

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Amount of Calcium, Not Calcium Progression, May Be Best for Gauging CV Risk

新分析质疑低密度脂蛋白胆固醇“越低越好”的说法，但专家仍呼吁应注意

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Mammogram-Derived Clues to Cardiovascular Disease Often Unreported and Ignored

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Lilly Provides Update on Evacetrapib Phase 3 Trial

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Post Angiography Testosterone Therapy Increases Cardiovascular Events in High-Risk Men

Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN

Endothelial Shear Stress Works as a PREDICTION Tool

Calcium Scanning May Lower CAD Risk at No Extra Cost

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content